Compare GRNQ & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRNQ | ONCO |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 4.3M |
| IPO Year | 2018 | 2022 |
| Metric | GRNQ | ONCO |
|---|---|---|
| Price | $1.74 | $1.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 46.7K | 45.8K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,110,208.00 | $1,223,751.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.04 | N/A |
| 52 Week Low | $0.84 | $1.84 |
| 52 Week High | $2.50 | $179.35 |
| Indicator | GRNQ | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 54.78 | 32.04 |
| Support Level | $1.60 | $2.53 |
| Resistance Level | $1.88 | $2.13 |
| Average True Range (ATR) | 0.11 | 0.31 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 65.00 | 0.26 |
Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust and wealth management. Its segments include Service business engaged in the provision of corporate advisory and business solution services; Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong and Malaysia; and Digital business segment engaged in provision of digital platform and trading of digital assets.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.